Recombinant human IL-21-expressing oncolytic vaccinia virus injection

BIOLOGICAL3 trials

Sponsors

Hangzhou Converd Co., Ltd.

Conditions

Advanced Pancreatic CancerAdvanced Solid Tumors

Phase 1

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

Active, not recruitingNCT05914376

Hangzhou Converd Co., Ltd.Advanced Solid Tumors

Start: 2023-07-05End: 2027-06-10Target: 24Updated: 2026-02-27

Phase 2

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

RecruitingNCT07006077

Hangzhou Converd Co., Ltd.Advanced Pancreatic Cancer

Start: 2025-05-29End: 2029-03-05Target: 12Updated: 2026-02-27

Unknown Phase

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

RecruitingNCT07185243

Hangzhou Converd Co., Ltd.Advanced Solid Tumors

Start: 2025-06-23End: 2028-06-30Target: 24Updated: 2025-09-22

Related Papers

Phase I study of hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, as monotherapy in advanced solid tumors.

Journal of Clinical Oncology2025-05-28